Novel strategies for the treatment of sepsis (original) (raw)

• Angus, D.C. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303–1310 (2001).
  Article CAS Google Scholar
• Bennett, I.L. et al. The effectiveness of hydrocortisone in the management of severe infection. JAMA 183, 462–465 (1963).
  Article Google Scholar
• Lefering, R. & Neugebauer, E.A. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. 23, 1294–1303 (1995).
  Article CAS Google Scholar
• Annane, D. et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288, 862–871 (2002).
  Article CAS Google Scholar
• Meduri, G.U. et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 280, 159–165 (1998).
  Article CAS Google Scholar
• Meduri, G.U., Tolley, E.A., Chrousos, G.P. & Stentz, F. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am. J. Respir. Crit. Care Med. 165, 983–991 (2002).
  Article Google Scholar
• Meduri, G.U., Kanangat, S., Stefan, J., Tolley, E. & Schaberg, D. Cytokines IL-1β, IL-6, and TNF-α enhance in vitro growth of bacteria. Am. J. Respir Crit. Care Med. 160, 961–967 (1999).
  Article CAS Google Scholar
• Kanangat, S. et al. Effects of cytokines and endotoxin on the intracellular growth of bacteria. Infect. Immun. 67, 2834–2840 (1999).
  CAS PubMed PubMed Central Google Scholar
• Davis, C.E., Brown, K.R., Douglas, H., Tate, W.J & Braude, A.I. Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J. Immunol. 102, 563–572 (1969).
  CAS PubMed Google Scholar
• Cohen, J. Adjunctive therapy in sepsis: a critical analysis of the clinical trial programme. Br. Med. Bull. 55, 212–225 (1999).
  Article CAS Google Scholar
• Bone, R.C. et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit. Care Med. 23, 994–1006 (1995).
  Article CAS Google Scholar
• Ziegler, E.J. et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324, 429–436 (1991).
  Article CAS Google Scholar
• Warren, H.S. et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177, 89–97 (1993).
  Article CAS Google Scholar
• Michie, H.R. et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104, 280–286 (1988).
  CAS PubMed Google Scholar
• Beutler, B., Milsark, I.W. & Cerami, A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229, 869–871 (1985).
  Article CAS Google Scholar
• Tracey, K.J. et al. Shock and tissue injury induced by recombinant human cachectin. Science 234, 470–474 (1986).
  Article CAS Google Scholar
• Tracey, K.J. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662–664 (1987).
  Article CAS Google Scholar
• Reinhart, K. & Karzai, W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29, S121–S125 (2001).
  Article CAS Google Scholar
• Okusawa, S., Gelfand, J.A., Ikejima, T., Connolly, R.J. & Dinarello, C.A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. 81, 1162–1172 (1988).
  Article CAS Google Scholar
• Ohlsson, K., Bjork, P., Bergenfeldt, M., Hageman, R. & Thompson, R.C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348, 550–552 (1990).
  Article CAS Google Scholar
• Fisher, C.J., Jr. et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271, 1836–1843 (1994).
  Article Google Scholar
• Opal, S.M. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115–1124 (1997).
  Article CAS Google Scholar
• Dhainaut, J.F. et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit. Care Med. 22, 1720–1728 (1994).
  Article CAS Google Scholar
• Dhainaut, J.F. et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit. Care Med. 26, 1963–1971 (1998).
  Article CAS Google Scholar
• Bernard, G.R. et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N. Engl. J. Med. 336, 912–918 (1997).
  Article CAS Google Scholar
• Vincent, J.L. et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med. 27, 1578–1583 (2001).
  Article CAS Google Scholar
• Yu, M. & Tomasa, G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit. Care Med. 21, 1635–1642 (1993).
  Article CAS Google Scholar
• Spies, C.D. et al. Influence of _N_-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. 22, 1738–1746 (1994).
  Article CAS Google Scholar
• Schilling, J., Cakmakci, M., Battig, U. & Geroulanos, S. A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-l-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med. 19, 227–231 (1993).
  Article CAS Google Scholar
• Lorente, J.A., Landin, L., De Pablo, R., Renes, E. & Liste, D. L-arginine pathway in the sepsis syndrome. Crit. Care Med. 21, 1287–1295 (1993).
  Article CAS Google Scholar
• Avontuur, J.A., Tutein Nolthenius, R.P., van Bodegom, J.W. & Bruining, H.A. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. 26, 660–667 (1998).
  Article CAS Google Scholar
• Fein, A.M. et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277, 482–487 (1997).
  Article CAS Google Scholar
• Staubach, K.H. et al. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch. Surg. 133, 94–100 (1998).
  Article CAS Google Scholar
• Zeni, F. et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit. Care Med. 24, 207–214 (1996).
  Article CAS Google Scholar
• Fronhoffs, S. et al. The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med. 26, 1566–1570 (2000).
  Article CAS Google Scholar
• Healy, D.P. New and emerging therapies for sepsis. Ann. Pharmacother. 36, 648–654 (2002).
  Article CAS Google Scholar
• van der Poll, T. Immunotherapy of sepsis. Lancet Infect. Dis. 1, 165–174 (2001).
  Article CAS Google Scholar
• Vincent, J.L., Sun, Q. & Dubois, M.J. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin. Infect. Dis. 34, 1084–1093 (2002).
  Article CAS Google Scholar
• Warren, B.L. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869–1878 (2001).
  Article CAS Google Scholar
• Bernard, G.R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).
  Article CAS Google Scholar
• Warren, H.S., Suffredini, A.F., Eichacker, P.Q. & Munford, R.S. Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 1027–1030 (2002).
  Article Google Scholar
• Riewald, M., Petrovan, R.J., Donner, A., Mueller, B.M. & Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880–1882 (2002).
  Article CAS Google Scholar
• Bustin, M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol. Cell. Biol. 19, 5237–5246 (1999).
  Article CAS Google Scholar
• Wang, H., Yang, H., Czura, C.J., Sama, A.E. & Tracey, K.J. HMGB1 as a late mediator of lethal systemic inflammation. Am. J. Respir. Crit. Care Med. 164, 1768–1773 (2001).
  Article CAS Google Scholar
• Andersson, U. et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565–570 (2000).
  Article CAS Google Scholar
• Wang, H. et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251 (1999).
  Article CAS Google Scholar
• Fiuza, C. et al. Inflammatory promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652–2660(2002).
  Article Google Scholar
• Sappington, P.L. et al. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790–802 (2002).
  Article CAS Google Scholar
• Ulloa, L. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc. Natl. Acad. Sci. USA 99, 12351–12356 (2002).
  Article CAS Google Scholar
• Calandra, T., Bernhagen, J., Mitchell, R.A. & Bucala, R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 179, 1895–1902 (1994).
  Article CAS Google Scholar
• Bernhagen, J. et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365, 756–759 (1993).
  Article CAS Google Scholar
• Bozza, M. et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341–346 (1999).
  Article CAS Google Scholar
• Calandra, T. et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377, 68–71 (1995).
  Article CAS Google Scholar
• Calandra, T. et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 6, 164–170 (2000).
  Article CAS Google Scholar
• Gando, S. et al. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med. 27, 1187–1193 (2001).
  Article CAS Google Scholar
• Lehmann, L.E. et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med. 27, 1412–1415 (2001).
  Article CAS Google Scholar
• Satoskar, A.R., Bozza, M., Rodriguez Sosa, M., Lin, G. & David, J.R. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous Leishmania major infection. Infect. Immun. 69, 906–911 (2001).
  Article CAS Google Scholar
• Koebernick, H. et al. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against Salmonella typhimurium. Proc. Natl. Acad. Sci. USA 99, 13681–13686 (2002).
  Article CAS Google Scholar
• Calandra, T., Spiegel, L.A., Metz, C.N. & Bucala, R. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. Proc. Natl. Acad. Sci. USA 95, 11383–11388 (1998).
  Article CAS Google Scholar
• Mitchell, R.A. et al. Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc. Natl. Acad. Sci. USA 99, 345–350 (2002).
  Article CAS Google Scholar
• Roger, T., David, J., Glauser, M.P. & Calandra, T. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414, 920–924 (2001).
  Article CAS Google Scholar
• Shin, H.S., Snyderman, R., Friedman, E., Mellors, A. & Mayer, M.M. Chemotactic and anaphylatoxic fragment cleaved from the fifth component of guinea pig complement. Science 162, 361–363 (1968).
  Article CAS Google Scholar
• Goldstein, I.M. & Weissmann, G. Generation of C5-derived lysosomal enzyme-releasing activity (C5a) by lysates of leukocyte lysosomes. J. Immunol. 113, 1583–1588 (1974).
  CAS Google Scholar
• Sacks, T., Moldow, C.F., Craddock, P.R., Bowers, T.K. & Jacob, H.S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J. Clin. Invest. 61, 1161–1167 (1978).
  Article CAS Google Scholar
• Schumacher, W.A., Fantone, J.C., Kunkel, S.E., Webb, R.C. & Lucchesi, B.R. The anaphylatoxins C3a and C5a are vasodilators in the canine coronary vasculature in vitro and in vivo. Agents Actions 34, 345–349 (1991).
  Article CAS Google Scholar
• Guo, R.F. et al. Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J. Clin. Invest. 106, 1271–1280 (2000).
  Article CAS Google Scholar
• Riedemann, N.C. et al. C5a receptor and thymocyte apoptosis in sepsis. FASEB J. 16, 887–888 (2002).
  Article CAS Google Scholar
• Huber-Lang, M. et al. Role of C5a in multiorgan failure during sepsis. J. Immunol. 166, 1193–1199 (2001).
  Article CAS Google Scholar
• Czermak, B.J. et al. Protective effects of C5a blockade in sepsis. Nat. Med. 5, 788–792 (1999).
  Article CAS Google Scholar
• Riedemann, N.C. et al. Increased C5a receptor expression in sepsis. J. Clin. Invest. 110, 101–108 (2002).
  Article CAS Google Scholar
• Huber-Lang, M.S. et al. Complement-induced impairment of innate immunity during sepsis. J. Immunol. 169, 3223–3231 (2002).
  Article CAS Google Scholar
• Gerard, N.P. & Gerard, C. The chemotactic receptor for human C5a anaphylatoxin. Nature 349, 614–617 (1991).
  Article CAS Google Scholar
• Riedemann, N.C. et al. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170, 503–507 (2003).
  Article CAS Google Scholar
• Fitch, J.C. et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 100, 2499–2506 (1999).
  Article CAS Google Scholar
• Oberholzer, C., Oberholzer, A., Clare-Salzler, M. & Moldawer, L.L. Apoptosis in sepsis: a new target for therapeutic exploration. FASEB J. 15, 879–892 (2001).
  Article CAS Google Scholar
• Hotchkiss, R.S. et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc. Natl. Acad. Sci. USA 96, 14541–14546 (1999).
  Article CAS Google Scholar
• Hotchkiss, R.S. et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J. Immunol. 162, 4148–4156 (1999).
  CAS PubMed Google Scholar
• Hotchkiss, R.S. et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 166, 6952–6963 (2001).
  Article CAS Google Scholar
• Eichacker, P.Q. et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197–1205 (2002).
  Article Google Scholar